Diuretics Versus Volume Expansion in the Initial Management of Acute Intermediate High-Risk Pulmonary Embolism
Aims The very early management of pulmonary embolism (PE), a part from antithrombotic treatment, has been little studied. Our aim was to compare the effects of diuretic therapy (DT) versus volume expansion (VE) in patients hospitalized for PE with RV dysfunction. Methods and Results We conducted a randomized open-label multicentric study including patients with intermediate high-risk PE. Patients were randomized between diuretics or saline infusion. The primary endpoint was time to troponin (Tp) normalization. Secondary endpoints were time to normalization of B-type natriuretic peptide (BNP), changes in echocardiographic RV function parameters and treatment tolerance. Sixty patients presenting intermediate high-risk PE were randomized. Thirty received DT and 30 VE. We noted no changes in Tp kinetics between the two groups. In contrast, faster normalization of BNP was obtained in the DT group: 56 [28–120] vs 108 [48–144] h: p = 0.05, with a shorter time to 50%-decrease from peak value 36 [24–48] vs 54 [41–67] h, p = 0.003 and a higher rate of patients with a lower BNP concentration within the first 12 h (42% vs 12% p < 0.001). RV echocardiographic parameters were unchanged between the groups. One dose 40 mg furosemide was well-tolerated and not associated with any serious adverse events. Conclusion In the acute management of intermediate high-risk PE, initial therapy including diuretic treatment is well-tolerated and safe. Although changes in Tp kinetics and echocardiographic RV dysfunction parameters did not differ, normalization of BNP is achieved more quickly in the DT group. This finding, which need to be confirmed in trials with clinical end points, may reflects a rapid improvement in RV function using one dose 40 mg furosemide. Trial Registry Clinical Trial Registration NCT02531581..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:200 |
|---|---|
| Enthalten in: |
Lung - 200(2022), 2 vom: Apr., Seite 179-185 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ferrari, Emile [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 |
|---|
| doi: |
10.1007/s00408-022-00530-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2078527319 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2078527319 | ||
| 003 | DE-627 | ||
| 005 | 20230514002544.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00408-022-00530-5 |2 doi | |
| 035 | |a (DE-627)OLC2078527319 | ||
| 035 | |a (DE-He213)s00408-022-00530-5-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Ferrari, Emile |e verfasserin |0 (orcid)0000-0002-8233-6039 |4 aut | |
| 245 | 1 | 0 | |a Diuretics Versus Volume Expansion in the Initial Management of Acute Intermediate High-Risk Pulmonary Embolism |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 | ||
| 520 | |a Aims The very early management of pulmonary embolism (PE), a part from antithrombotic treatment, has been little studied. Our aim was to compare the effects of diuretic therapy (DT) versus volume expansion (VE) in patients hospitalized for PE with RV dysfunction. Methods and Results We conducted a randomized open-label multicentric study including patients with intermediate high-risk PE. Patients were randomized between diuretics or saline infusion. The primary endpoint was time to troponin (Tp) normalization. Secondary endpoints were time to normalization of B-type natriuretic peptide (BNP), changes in echocardiographic RV function parameters and treatment tolerance. Sixty patients presenting intermediate high-risk PE were randomized. Thirty received DT and 30 VE. We noted no changes in Tp kinetics between the two groups. In contrast, faster normalization of BNP was obtained in the DT group: 56 [28–120] vs 108 [48–144] h: p = 0.05, with a shorter time to 50%-decrease from peak value 36 [24–48] vs 54 [41–67] h, p = 0.003 and a higher rate of patients with a lower BNP concentration within the first 12 h (42% vs 12% p < 0.001). RV echocardiographic parameters were unchanged between the groups. One dose 40 mg furosemide was well-tolerated and not associated with any serious adverse events. Conclusion In the acute management of intermediate high-risk PE, initial therapy including diuretic treatment is well-tolerated and safe. Although changes in Tp kinetics and echocardiographic RV dysfunction parameters did not differ, normalization of BNP is achieved more quickly in the DT group. This finding, which need to be confirmed in trials with clinical end points, may reflects a rapid improvement in RV function using one dose 40 mg furosemide. Trial Registry Clinical Trial Registration NCT02531581. | ||
| 650 | 4 | |a Pulmonary embolism | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Diuretics | |
| 650 | 4 | |a Volume expansion | |
| 700 | 1 | |a Sartre, Benjamin |4 aut | |
| 700 | 1 | |a Labbaoui, Mohamed |4 aut | |
| 700 | 1 | |a Heme, Nathan |4 aut | |
| 700 | 1 | |a Asarisi, Florian |4 aut | |
| 700 | 1 | |a Redjimi, Nassim |4 aut | |
| 700 | 1 | |a Fourrier, Etienne |4 aut | |
| 700 | 1 | |a Squara, Fabien |4 aut | |
| 700 | 1 | |a Bun, Sithy |4 aut | |
| 700 | 1 | |a Berkane, Nathalie |4 aut | |
| 700 | 1 | |a Breittmayer, Jean Philippe |4 aut | |
| 700 | 1 | |a Doyen, Denis |4 aut | |
| 700 | 1 | |a Moceri, Pamela |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung |d Springer US, 1976 |g 200(2022), 2 vom: Apr., Seite 179-185 |w (DE-627)129089729 |w (DE-600)6165-7 |w (DE-576)014424649 |x 0341-2040 |7 nnns |
| 773 | 1 | 8 | |g volume:200 |g year:2022 |g number:2 |g month:04 |g pages:179-185 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00408-022-00530-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_2018 | ||
| 951 | |a AR | ||
| 952 | |d 200 |j 2022 |e 2 |c 04 |h 179-185 | ||